# Phase 15 — Enterprise Trust + Procurement Readiness: Report

STATUS: **PASS**. Audit-driven, documentation-only. This platform's
procurement-readiness posture — `compliance/`'s SOC2/CAIQ/NIST-CSF/DPA/
vendor-risk artifacts, `SECURITY_ASSURANCE_CASE.md`'s 911-line threat
model and evidence matrix, `ENTERPRISE_SECURITY.md`, `SECURITY.md`,
`SLA.md`, `GOVERNANCE.md` — was already extraordinarily comprehensive
before this phase started. Nothing here needed building; one real gap
(staleness) needed fixing.

## Objective

Per `docs/enterprise-neural/15_PHASE15_DESIGN.md`: verify the master
directive's Phase 15 ("Enterprise Trust + Procurement Readiness")
against the real, existing documentation — per directive rule 63,
close only genuine gaps rather than duplicating what already exists.

## Current state before phase

`compliance/` (37 files): `SOC2_READINESS.md`, `SOC2_ALTERNATIVE_PATH.md`,
`CAIQ_SELF_ASSESSMENT.md` plus the completed CAIQ v4.0.3 spreadsheet,
`NIST_CSF_SELF_ASSESSMENT.md`, `DPA_TEMPLATE.md` +
`DPA_ATTORNEY_SCOPE_BRIEF.md`, `VENDOR_RISK_ASSESSMENT.md`,
`INCIDENT_RESPONSE_RUNBOOK.md`, a dated tabletop-exercise record,
`KEY_MANAGEMENT.md`, `PROJECT_CONTINUITY_PLAN.md`,
`SIGNED_VERSION_TAGS.md`, three `OPENSSF_*` evidence/gap-analysis
documents, `INTERNAL_SECURITY_REVIEW.md`. At the repository root:
`SECURITY_ASSURANCE_CASE.md` — a full threat model (24 threats across
STRIDE-adjacent categories), trust-boundary map, secure-design-
principles argument, and a 12-row Evidence Matrix mapping every
security claim to its control, implementation, real test files, and
CI check, with an honest "Known Limitations" section already naming
exactly the external gates (no independent pentest, no SOC 2/ISO
27001 certification) this session's own discipline has applied
throughout Phases 8-14.

## What was found

`SECURITY_ASSURANCE_CASE.md` stated "Last reviewed: 2026-08-19 ·
Platform version: 1.2.2" — both stale: the platform version had
already moved to 1.2.3 (per `pyproject.toml`) independent of this
directive's own work, and the Evidence Matrix's C4, C6, C11, and C12
rows predated Phases 11, 13, and 14's real, tested improvements.

## Architecture implemented

No architecture, no tests — this phase corrects references in an
existing document:

- **C4** (Runtime authority enforcement): added `UpstreamMCPExecutor`
  and its test files (`tests/test_citadel_execution_containment.py`,
  `tests/test_upstream_gateway.py`) alongside `InternalToolExecutor`
  — the residual-limitation note ("only covers... not direct library
  use") was narrower than reality even before Phase 11; corrected to
  "covers... internal tools and upstream-proxied calls alike."
- **C6** (Execution Permit/approval binding): added target-fingerprint
  drift detection (Execution Permit v2) and its dedicated tests
  alongside the pre-existing digest+consumed-flag binding.
- **C11** (Hash-chain tamper-evidence): added the evidence-bundle
  mitigating mechanism and Phase 13's proof that it detects exactly
  the attack `verify_chain()` alone cannot — while preserving the
  still-real limitation that no *automated* periodic external
  publication pipeline exists.
- **C12** (Fail-closed): broadened to cite Phase 14's generalized
  resilience matrix (`tests/test_resilience_fail_closed_matrix.py`)
  alongside the original evidence-write test, and named the three
  dependencies that remain untested for the same property.
- Bumped "Last reviewed" to 2026-08-28 and the platform-version
  reference to 1.2.3.

## Files created

- `docs/enterprise-neural/15_PHASE15_DESIGN.md`
- `docs/enterprise-neural/15_PHASE15_REPORT.md` (this file)

## Files modified

- `SECURITY_ASSURANCE_CASE.md` — Evidence Matrix rows C4, C6, C11, C12
  corrected; header dates/version corrected.
- `CHANGELOG.md`, `docs/enterprise-neural/PROGRESS_LEDGER.md`.

## Database migrations

None.

## Security properties added

None — this phase corrects documentation to accurately reflect
properties Phases 11, 13, and 14 already proved. No new claim is made
that isn't backed by a real, already-passing test.

## Privacy properties added

None new.

## Trust boundaries changed

None.

## Threats mitigated

None newly mitigated by this phase — it corrects the record of what's
already mitigated, both understating (C4, C6, C12 previously omitted
real, tested coverage) and appropriately still stating a real
limitation (C11's core gap remains genuinely open).

## Threats not yet mitigated — named explicitly, not glossed over

Unchanged from the document's own pre-existing §8 "Known Limitations":
no independent pentest, no SOC 2/ISO 27001 certification, SQLite
plaintext-on-disk absent host-volume encryption, no external evidence-
chain anchoring pipeline, no fuzz-testing, self-review only (not
independently reviewed). This phase did not close any of these — they
remain real, external, and correctly out of scope for a single phase
per directive rule 63's own reasoning (matching Phase 12's KMS/HSM and
Phase 13's external-anchoring-pipeline findings).

## Known limitations

This phase's own audit was not exhaustive across all 37 `compliance/`
files and every claim in `SECURITY_ASSURANCE_CASE.md`'s 24-threat
model — it targeted the Evidence Matrix specifically, since that's the
section most directly tied to this session's own recent, verifiable
work (Phases 11, 13, 14). A fuller pass across every compliance
document for staleness is real, separately-scoped future work, not
claimed complete here.

## Unit test results

None new this phase — no code changed, nothing to test.

## Integration test results

Not applicable.

## Property test results

Not applicable.

## Fuzz results

Not run.

## Adversarial test results

Not applicable — this phase is a documentation-accuracy audit, not a
new security boundary.

## Regression results

Full suite: **3132 passed, 1 skipped, 0 failed**, 129.98s
(`/tmp/full_run_phase15.log`) — identical to Phase 14's result, as
expected for a documentation-only change; run to confirm no
accidental regression, not because any was anticipated.

## Static analysis

Not applicable — no source or test file changed.

## Dependency audit

No new dependency.

## Secret scan

No secrets introduced.

## Supply-chain results

Not re-run this phase.

## Performance results

Not applicable.

## Backward-compatibility result

Fully backward compatible — documentation-only change.

## Migration result

Not applicable.

## Rollback procedure

Revert the `SECURITY_ASSURANCE_CASE.md` diff. Nothing else to revert.

## Documentation updated

`SECURITY_ASSURANCE_CASE.md`, `docs/enterprise-neural/15_PHASE15_DESIGN.md`,
this report, `PROGRESS_LEDGER.md`, `CHANGELOG.md`.

## Claims now supported by evidence

Every claim added to the Evidence Matrix in this phase (C4's
`UpstreamMCPExecutor` coverage, C6's target-fingerprint binding, C11's
bundle-export mitigation, C12's resilience matrix) was already true
and already regression-tested by Phases 11, 13, and 14 respectively —
this phase makes the assurance case's own record match that reality,
not a new claim being made for the first time.

## Claims still unsupported

Unchanged: no independent pentest, no SOC 2/ISO 27001 certification,
no automated external evidence-anchoring pipeline — all named
explicitly in the document's own §8, not glossed over by this phase's
edits.

## Errors found and fixed this phase

Two stale facts in `SECURITY_ASSURANCE_CASE.md`'s header (review date,
platform version) and four Evidence Matrix rows (C4, C6, C11, C12)
that undersold or omitted real, already-tested coverage. Corrected.

## Residual risks

The document's own pre-existing, honestly-stated external gates (no
pentest, no SOC 2/ISO 27001, no automated anchoring pipeline) remain
open — tracked here and in the ledger, unchanged by this phase.

## Next-phase dependencies

Phase 16 (Neural Scientific Evidence System) is next — the master
directive's original go-ahead explicitly grouped this with the
neural/BCI track (Phases 4-7, already completed with deliberately
typed-contract-only scope, no fabricated device/decoder). The same
discipline applies: audit what Phases 4-7 already established before
assuming any new scope.
